In short
A clinical trial is underway to assess the effectiveness of a drug containing Specific Nucleic Acid SNA-EBV in treating fatigue associated with Epstein-Barr Virus (EBV) infection. This randomized, placebo-controlled, double-blind study aims to compare the efficacy of 2LEBV® and 2LXFS® in reducing fatigue severity and other EBV-related symptoms in patients aged 12 and older. The trial will evaluate various aspects of fatigue, immune system responses, and overall patient well-being over a 12-month period.
At a glance
- Study Type
- Randomized, placebo-controlled, double-blind clinical trial
- Main Objective
- Evaluate efficacy of 2LEBV® and 2LXFS® on fatigue severity in EBV-infected patients
- Primary Endpoint
- General fatigue scale of MFI-20 questionnaire at 6 months
- Secondary Endpoints
- Other fatigue dimensions, EBV-related symptoms, lymphocyte typing, IgG levels, safety
- Study Duration
- 12 months with assessments at 3, 6, and 12 months
- Key Inclusion Criteria
- Age ≥12, significant fatigue for ≥1 month, ≥2 other EBV-related symptoms, positive EBV serology
- Key Exclusion Criteria
- Recent homeopathic treatments, immunosuppressive therapy, psychiatric treatments
- Active Substance
- Specific Nucleic Acid SNA-EBV, along with other nucleic acids and interleukins
What is SPECIFIC NUCLEIC ACID SNA-EBV?
SPECIFIC NUCLEIC ACID SNA-EBV, also known as SNA-EBV or Specific Nucleic Acid - Epstein Barr Virus, is an investigational treatment being studied for its potential to help patients with Epstein-Barr Virus (EBV) infection. It is part of a medication called 2LEBV, which contains several active ingredients including SNA-EBV.
Target Condition: Epstein-Barr Virus Infection
Epstein-Barr Virus (EBV) is a common virus that can cause various symptoms and health issues. When a person is infected with EBV, they may experience symptoms such as fatigue, fever, sore throat, and swollen lymph nodes. In some cases, the infection can lead to prolonged fatigue and other persistent symptoms.
Current Clinical Trial
A clinical trial is currently underway to evaluate the effectiveness of 2LEBV (which contains SNA-EBV) in treating fatigue associated with EBV infection. This study is described as a "Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infection".
Key points about the trial:
- It aims to compare the effectiveness of 2LEBV or a combination of 2LXFS/2LEBV against a placebo in reducing fatigue severity
- The study will measure fatigue using a questionnaire called MFI-20
- Other symptoms related to EBV infection will also be evaluated
- The trial will assess changes in the immune system by looking at lymphocyte (a type of white blood cell) levels and antibodies
How SNA-EBV May Work
While the exact mechanism is not fully explained in the trial information, SNA-EBV is described as a "specific nucleic acid." Nucleic acids are important biological molecules that include DNA and RNA. In this case, SNA-EBV may be designed to target specific aspects of the Epstein-Barr Virus or help the immune system respond to the virus more effectively.
Potential Benefits
The main goal of using SNA-EBV (as part of 2LEBV) is to reduce fatigue in patients with EBV infection. The clinical trial is also looking at other potential benefits, including:
- Improvement in other EBV-related symptoms
- Changes in the immune system response
- Long-term effects on fatigue and other symptoms (up to 12 months after treatment)
How SNA-EBV is Administered
SNA-EBV is part of a medication called 2LEBV, which comes in the form of granules in capsules that are meant to be opened. The medication is administered through oromucosal use, which means it's applied to the mucous membrane of the mouth.
Who Might Be Eligible for Treatment?
Based on the clinical trial criteria, potential candidates for this treatment include:
- Patients aged 12 years and older
- Those experiencing significant fatigue for 1 month or more
- Individuals with at least two other symptoms related to EBV infection
- Patients with a positive EBV serology (blood test showing evidence of EBV infection)
Safety Considerations
As with any medical treatment, safety is an important consideration. The clinical trial is monitoring for any adverse events or side effects that may occur during treatment. It's important to note that this is still an investigational treatment, and more research is needed to fully understand its safety profile and effectiveness.